

**Table S1** Extrathoracic metastasis sites of patients with different characteristics<sup>a</sup>

Characteristics	Brain (N=60)	Bone (N=42)	Liver (N=18)	Distant lymph node (N=6)	Other site(s) (N=90)	Multiple sites (N=35)	Total (N=251)
Age (years)							
≤50	5 (27.8)	1 (5.6)	2 (11.1)	0 (0.0)	7 (38.9)	3 (16.7)	18 (100.0)
51–60	13 (35.1)	7 (18.9)	2 (5.4)	1 (2.7)	12 (32.4)	2 (5.4)	37 (100.0)
61–70	23 (28.4)	11 (13.6)	3 (3.7)	1 (1.2)	26 (32.1)	17 (21)	81 (100.0)
71–80	17 (19.3)	18 (20.5)	7 (8)	4 (4.5)	33 (37.5)	9 (10.2)	88 (100.0)
≥81	2 (7.4)	5 (18.5)	4 (14.8)	0 (0.0)	12 (44.4)	4 (14.8)	27 (100.0)
Sex							
Female	29 (22.7)	19 (14.8)	10 (7.8)	2 (1.6)	43 (33.6)	25 (19.5)	128 (100.0)
Male	31 (25.2)	23 (18.7)	8 (6.5)	4 (3.3)	47 (38.2)	10 (8.1)	123 (100.0)
Race							
White	48 (23.5)	36 (17.6)	13 (6.4)	5 (2.5)	72 (35.3)	30 (14.7)	204 (100.0)
Black	9 (36.0)	3 (12.0)	5 (20.0)	1 (4.0)	4 (16.0)	3 (12.0)	25 (100.0)
Others <sup>b</sup>	3 (13.6)	3 (13.6)	0 (0.0)	0 (0.0)	14 (63.6)	2 (9.1)	22 (100.0)
Hispanic <sup>c</sup>							
No	53 (23.8)	36 (16.1)	17 (7.6)	6 (2.7)	81 (36.3)	30 (13.5)	223 (100.0)
Yes	7 (25.0)	6 (21.4)	1 (3.6)	0 (0.0)	9 (32.1)	5 (17.9)	28 (100.0)
Primary site							
Bronchus	0 (0.0)	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (100.0)
Upper lobe	24 (25.3)	16 (16.8)	2 (2.1)	3 (3.2)	39 (41.1)	11 (11.6)	95 (100.0)
Middle lobe	36 (23.4)	26 (16.9)	14 (9.1)	3 (1.9)	51 (33.1)	24 (15.6)	154 (100.0)
Lower lobe	0 (0.0)	1 (25.0)	2 (50.0)	0 (0.0)	1 (25.0)	0 (0.0)	4 (100.0)
Laterality							
Right	44 (27.3)	33 (20.5)	11 (6.8)	3 (1.9)	53 (32.9)	17 (10.6)	161 (100.0)
Left	1 (7.7)	2 (15.4)	0 (0.0)	0 (0.0)	8 (61.5)	2 (15.4)	13 (100.0)
Size (cm)							
≤1	15 (20.5)	6 (8.2)	5 (6.8)	3 (4.1)	28 (38.4)	16 (21.9)	73 (100.0)
(1, 2]	38 (27.3)	24 (17.3)	7 (5)	2 (1.4)	47 (33.8)	21 (15.1)	139 (100.0)
(2, 3]	22 (19.6)	18 (16.1)	11 (9.8)	4 (3.6)	43 (38.4)	14 (12.5)	112 (100.0)
Pleural invasion							
PL0	38 (26.8)	33 (23.2)	12 (8.5)	6 (4.2)	29 (20.4)	24 (16.9)	142 (100.0)
PL1/2	15 (25.9)	6 (10.3)	4 (6.9)	0 (0.0)	29 (50.0)	4 (6.9)	58 (100.0)
PL3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8 (80.0)	2 (20.0)	10 (100.0)
PL-NOS <sup>d</sup>	7 (17.1)	3 (7.3)	2 (4.9)	0 (0.0)	24 (58.5)	5 (12.2)	41 (100.0)

**Table S1** (continued)

Table S1 (continued)

Characteristics	Brain (N=60)	Bone (N=42)	Liver (N=18)	Distant lymph node (N=6)	Other site(s) (N=90)	Multiple sites (N=35)	Total (N=251)
<b>Malignancy history</b>							
No	52 (25.4)	32 (15.6)	14 (6.8)	5 (2.4)	72 (35.1)	30 (14.6)	205 (100.0)
Yes, breast	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (50.0)	1 (50.0)	2 (100.0)
Yes, colon and rectum	2 (22.2)	4 (44.4)	1 (11.1)	0 (0.0)	2 (22.2)	0 (0.0)	9 (100.0)
Yes, lung and bronchus	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (100.0)	0 (0.0)	2 (100.0)
Yes, multiple	4 (14.3)	4 (14.3)	3 (10.7)	1 (3.6)	13 (46.4)	3 (10.7)	28 (100.0)
Yes, others <sup>e</sup>	2 (40)	2 (40)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)	5 (100.0)
<b>Marital status</b>							
Never married	8 (21.6)	7 (18.9)	4 (10.8)	1 (2.7)	8 (21.6)	9 (24.3)	37 (100.0)
Married	36 (23.8)	26 (17.2)	9 (6)	2 (1.3)	63 (41.7)	15 (9.9)	151 (100.0)
Others	16 (25.4)	9 (14.3)	5 (7.9)	3 (4.8)	19 (30.2)	11 (17.5)	63 (100.0)
<b>Income<sup>f</sup></b>							
<50,000\$	8 (30.8)	1 (3.8)	3 (11.5)	1 (3.8)	8 (30.8)	5 (19.2)	26 (100.0)
50,000–74,999\$	21 (21.6)	20 (20.6)	10 (10.3)	1 (1)	32 (33)	13 (13.4)	97 (100.0)
≥75,000\$	31 (24.2)	21 (16.4)	5 (3.9)	4 (3.1)	50 (39.1)	17 (13.3)	128 (100.0)

<sup>a</sup>, Values are numbers (percentages), and percentages may not total 100 because of rounding. “Other site(s)” might include multiple extrathoracic metastases, but in our study was considered as only one extrathoracic metastases; <sup>b</sup>, Others included Asian/Pacific Islander and American Indian/Alaska Native; <sup>c</sup>, “Hispanic” indicated Americans from Latin America; <sup>d</sup>, “PL-NOS” indicated pleural invasion but no other specific information about PL1/2 or PL3; <sup>e</sup>, “Yes, others” indicated cancer history not including breast, lung and bronchus, colon and rectum, or multiple cancer history; <sup>f</sup>, “Income” indicated median household income inflation adjusted to 2021.